THOR MEDICAL ASA (TRMED.OL) Fundamental Analysis & Valuation

OSL:TRMED • NO0010597883

Current stock price

5.15 NOK
+0.14 (+2.79%)
Last:

This TRMED.OL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TRMED.OL Profitability Analysis

1.1 Basic Checks

  • In the past year TRMED has reported negative net income.
  • In the past year TRMED has reported a negative cash flow from operations.
  • In the past 5 years TRMED always reported negative net income.
  • In the past 5 years TRMED always reported negative operating cash flow.
TRMED.OL Yearly Net Income VS EBIT VS OCF VS FCFTRMED.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • TRMED has a Return On Assets of -8.19%. This is in the better half of the industry: TRMED outperforms 64.20% of its industry peers.
  • Looking at the Return On Equity, with a value of -12.72%, TRMED is in the better half of the industry, outperforming 69.14% of the companies in the same industry.
Industry RankSector Rank
ROA -8.19%
ROE -12.72%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRMED.OL Yearly ROA, ROE, ROICTRMED.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • TRMED does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRMED.OL Yearly Profit, Operating, Gross MarginsTRMED.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2025 -20K -40K -60K -80K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. TRMED.OL Health Analysis

2.1 Basic Checks

  • TRMED does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TRMED has more shares outstanding than it did 1 year ago.
  • TRMED has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, TRMED has a worse debt to assets ratio.
TRMED.OL Yearly Shares OutstandingTRMED.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
TRMED.OL Yearly Total Debt VS Total AssetsTRMED.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • TRMED has an Altman-Z score of 4.34. This indicates that TRMED is financially healthy and has little risk of bankruptcy at the moment.
  • TRMED has a better Altman-Z score (4.34) than 67.90% of its industry peers.
  • A Debt/Equity ratio of 0.35 indicates that TRMED is not too dependend on debt financing.
  • TRMED has a Debt to Equity ratio (0.35) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z 4.34
ROIC/WACCN/A
WACC8.2%
TRMED.OL Yearly LT Debt VS Equity VS FCFTRMED.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 4.57 indicates that TRMED has no problem at all paying its short term obligations.
  • TRMED has a better Current ratio (4.57) than 79.01% of its industry peers.
  • TRMED has a Quick Ratio of 4.50. This indicates that TRMED is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of TRMED (4.50) is better than 79.01% of its industry peers.
Industry RankSector Rank
Current Ratio 4.57
Quick Ratio 4.5
TRMED.OL Yearly Current Assets VS Current LiabilitesTRMED.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. TRMED.OL Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 22.64% on average over the next years. This is a very strong growth
  • TRMED is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 385.94% yearly.
EPS Next Y24.44%
EPS Next 2Y23.83%
EPS Next 3Y22.64%
EPS Next 5YN/A
Revenue Next Year1850%
Revenue Next 2Y793.04%
Revenue Next 3Y385.95%
Revenue Next 5YN/A

3.3 Evolution

TRMED.OL Yearly Revenue VS EstimatesTRMED.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 2028 50M 100M 150M 200M
TRMED.OL Yearly EPS VS EstimatesTRMED.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. TRMED.OL Valuation Analysis

4.1 Price/Earnings Ratio

  • TRMED reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TRMED is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRMED.OL Price Earnings VS Forward Price EarningsTRMED.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRMED.OL Per share dataTRMED.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • TRMED's earnings are expected to grow with 22.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.83%
EPS Next 3Y22.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TRMED.OL Dividend Analysis

5.1 Amount

  • TRMED does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRMED.OL Fundamentals: All Metrics, Ratios and Statistics

THOR MEDICAL ASA

OSL:TRMED (4/20/2026, 9:58:09 AM)

5.15

+0.14 (+2.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)N/A
Inst Owners7.29%
Inst Owner ChangeN/A
Ins Owners2%
Ins Owner ChangeN/A
Market Cap1.85B
Revenue(TTM)439.00K
Net Income(TTM)-58.01M
Analysts40
Price Target4.34 (-15.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-9.68%
EPS NY rev (3m)15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)34.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4220.65
P/FCF N/A
P/OCF N/A
P/B 4.06
P/tB 9.66
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS1.27
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -8.19%
ROE -12.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 349.4%
Cap/Sales 16653.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.57
Quick Ratio 4.5
Altman-Z 4.34
F-ScoreN/A
WACC8.2%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y24.44%
EPS Next 2Y23.83%
EPS Next 3Y22.64%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1850%
Revenue Next 2Y793.04%
Revenue Next 3Y385.95%
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year39.02%
EBIT Next 3Y36.67%
EBIT Next 5YN/A
FCF growth 1Y-400.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-98.27%
OCF growth 3YN/A
OCF growth 5YN/A

THOR MEDICAL ASA / TRMED.OL Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for THOR MEDICAL ASA?

ChartMill assigns a fundamental rating of 3 / 10 to TRMED.OL.


What is the valuation status of THOR MEDICAL ASA (TRMED.OL) stock?

ChartMill assigns a valuation rating of 1 / 10 to THOR MEDICAL ASA (TRMED.OL). This can be considered as Overvalued.


How profitable is THOR MEDICAL ASA (TRMED.OL) stock?

THOR MEDICAL ASA (TRMED.OL) has a profitability rating of 1 / 10.